42 results about "Ovarian cell" patented technology

The invention discloses a C-shaped aftosa subunit genetic engineering vaccine and a preparation method thereof. The C-shaped aftosa subunit vaccine has the main component of a mixture formed by C-shaped aftosa structure protein VP1 and VP3 according to the protein content ratio being 1 / 1, wherein the C-shaped aftosa structure protein VP1 and VP3 is eukaryotic expression products of C-shaped aftosa virus gene VP1 and VP3, in particular to products of C-shaped aftosa antigenic gene VP1 and VP3 expressed in a Chinese hamster ovarian cell (CHO / dhfr-cell) expression system.

Glycosylated Antitumor Ether Lipids (GAELs) kill cancer cells by a nonapoptotic pathway which is an attractive strategy to avoid resistance. To further optimize the antitumor effect, we prepared various analogs of di-, and tri-cationic GAEL analogs differing in the nature of the sugar (D-glucose or L-glucose), the anomeric linkage as well as position of the glycerolipid moiety. The di- and tri-cationic GAELs were synthesized and their in vitro anticancer properties were evaluated against drug resistant and aggressively growing cancer cell lines derived from human breast, prostate, pancreatic and ovarian cancers. The most potent dicationic GAEL analogs were also studied against cancer stem cells obtained from breast BT 474, prostate DU145 and ovarian A2780cp cell lines. Our results indicate that the number of positive charges, the position of the amino substituents and the nature of the sugar have significant effects on the anticancer activities of these compounds. The most active analog kill 50% of the cells at concentration range of 0.5-5 μM and 90% of the cells at the concentration of 1-10 μM depending on type of cancer cells.